Non-Hodgkin's lymphomas

Clinical Obstetrics and Gynecology

Volumn 45, Issue 3, 2002, Pages 820-829

  Theodossiou, Chris ^a   Schwarzenberger, Paul ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY Y 90; PREDNISONE; PROCARBAZINE; PSORALEN; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG FATALITY; HUMAN; LABORATORY DIAGNOSIS; NONHODGKIN LYMPHOMA; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROGNOSIS; UNITED STATES; VINCRISTINE;

EID: 0036403790     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200209000-00029     Document Type: Review

References (23)

1. th Edition. Philadelphia: Lippincott Williams & Wilkins, 2001.
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7.
3. Glass AG, Karnell LH, Menck HR. The national cancer data base report on non-Hodgkin's lymphoma. Cancer. 1997;80:2311.
4. Rabkin KS, Devesa SS, Zahm S, et al. Increasing incidence of non-Hodgkin's lymphoma. Semin Hematol. 1993;30:286.
5. Corn MW, Marcus SM, Tophan A, et al. Will primary central nervous system lymphoma be the most common brain cancer diagnosed in the year 2000? Cancer. 1997;79:2409.
6. Cotte TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS. Incidence, presentation, and public health burden. Int J Cancer. 1997;73:645.
7. Hartge P, Devesa SS, Fraumeni JS. Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv. 1994;20:423.
8. Holford TR, Zheng T, Mayne ST, et al. Time trends in non-Hodgkin's lymphoma: Are they real? What do they mean? Cancer Res. 1992;52:5453.
9. The Non-Hodgkin's Lymphoma Pathologic Classification Group. NCI-sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112.
10. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361.
11. International Lymphoma Study Group. Classification of non-Hodgkin's lymphoma. Blood. 1996;89:3909.
12. Conlan MG, Bast M, Armitage JO, et al. Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between lymph nodes and bone marrow. J Clin Oncol. 1990;8:1163.
13. 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;8:1139.
14. Finke J, Slanina J, Lange W, et al. Persistence of circulating t(14; 18)-positive cells in long-term remission after radiation therapy for localized stage follicular lymphoma. J Clin Oncol. 1993;11:1668.
15. 131I tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918.
16. Gregory S, Zelenetz A, Knox S, et al. Bexxar is an effective and well-tolerated therapy in elderly patients with NHL. Proc ASCO. 2001;1136A.
17. Miller TP, Dahlberg, S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade NHL. N Engl J Med. 1998;339:21.
18. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced NHL. N Engl J Med. 1993;328:1002.
19. Coiffier B, Lepage E, Herbrecht R, et al. Rituximab plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim analysis of a randomized trial. Blood. 2000;96:223.
20. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987.
21. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med. 1995;333:1540.
22. Chen LT, Lin JT, Shyu RY, et al. Prospective study of Helicobacterpylori eradication therapy in stage IE high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol. 2001;19:4245.
23. Kaplan LD, Strauss DH, Testa MA, et al. Low dose compared with standard dose of m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med. 1997;336:1641.